299 related articles for article (PubMed ID: 27405680)
21. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
[TBL] [Abstract][Full Text] [Related]
22. Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc).
Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TAL; Walker ID
Int J Lab Hematol; 2019 Apr; 41(2):176-183. PubMed ID: 30556650
[TBL] [Abstract][Full Text] [Related]
23. Optimization of the thrombin generation test components to measure potency of factor VIII concentrates.
Jha NK; Shestopal SA; Gourley MJ; Woodle SA; Liang Y; Sarafanov AG; Weinstein M; Ovanesov MV
Haemophilia; 2016 Sep; 22(5):780-9. PubMed ID: 27038076
[TBL] [Abstract][Full Text] [Related]
24. Chromogenic factor VIII activity assay.
Moser KA; Adcock Funk DM
Am J Hematol; 2014 Jul; 89(7):781-4. PubMed ID: 24676945
[TBL] [Abstract][Full Text] [Related]
25. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
26. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B.
Adcock DM; Strandberg K; Shima M; Marlar RA
Int J Lab Hematol; 2018 Dec; 40(6):621-629. PubMed ID: 29979821
[TBL] [Abstract][Full Text] [Related]
27. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.
Sommer JM; Buyue Y; Bardan S; Peters RT; Jiang H; Kamphaus GD; Gray E; Pierce GF
Thromb Haemost; 2014 Nov; 112(5):932-40. PubMed ID: 25144892
[TBL] [Abstract][Full Text] [Related]
28. The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX.
Wilmot HV; Rakowski K; Gray E
Int J Lab Hematol; 2020 Dec; 42(6):810-818. PubMed ID: 32638532
[TBL] [Abstract][Full Text] [Related]
29. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
Kitchen S; Katterle Y; Beckmann H; Maas Enriquez M
J Thromb Haemost; 2016 Jun; 14(6):1192-9. PubMed ID: 27002680
[TBL] [Abstract][Full Text] [Related]
30. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
[TBL] [Abstract][Full Text] [Related]
31. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
[TBL] [Abstract][Full Text] [Related]
32. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
Mazurier C; Parquet-Gernez A; Goudemand M
Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
[TBL] [Abstract][Full Text] [Related]
33. A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.
Tiefenbacher S; Clausen WHO; Hansen M; Lützhøft R; Ezban M
Haemophilia; 2019 Sep; 25(5):893-901. PubMed ID: 31294905
[TBL] [Abstract][Full Text] [Related]
34. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.
St Ledger K; Feussner A; Kalina U; Horn C; Metzner HJ; Bensen-Kennedy D; Blackman N; Veldman A; Stowers A; Friedman KD
J Thromb Haemost; 2018 Mar; 16(3):555-564. PubMed ID: 29274194
[TBL] [Abstract][Full Text] [Related]
35. Potency labeling of novel factor VIII and factor IX concentrates: past experience and current strategy.
Hubbard AR
Semin Thromb Hemost; 2015 Nov; 41(8):849-54. PubMed ID: 25703515
[TBL] [Abstract][Full Text] [Related]
36. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.
Kitchen S; Signer-Romero K; Key NS
Haemophilia; 2015 Jul; 21(4):550-7. PubMed ID: 25688866
[TBL] [Abstract][Full Text] [Related]
37. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
[TBL] [Abstract][Full Text] [Related]
38. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
39. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products.
Mikaelsson M; Oswaldsson U
Semin Thromb Hemost; 2002 Jun; 28(3):257-64. PubMed ID: 12098085
[TBL] [Abstract][Full Text] [Related]
40. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.
Pahl S; Pavlova A; Driesen J; Müller J; Pötzsch B; Oldenburg J
Haemophilia; 2013 May; 19(3):392-8. PubMed ID: 23252674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
